Trade
Senores Pharmaceuticals share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,480.95(2.11%)July 15, 2026 15:20:43 PM IST
- NSE
- BSE
- Vol : 144.41 K (NSE + BSE)Last 20 day avg : 340.06 K
Senores Pharmaceuticals is trading 2.11% upper at Rs 1,480.95 as compared to its last closing price. Senores Pharmaceuticals has been trading in the price range of 1,481.05 & 1,454.00. Senores Pharmaceuticals has given 76.58% in this year & 6.84% in the last 5 days. Senores Pharmaceuticals has TTM P/E ratio 28.78 as compared to the sector P/E of 25.20.There are 4 analysts who have initiated coverage on Senores Pharmaceuticals. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 31.61 Crores in its last quarter.Listed peers of Senores Pharmaceuticals include Divi's Laboratories (1.67%), Cipla (-0.18%), Dr Reddy's Laboratories (-1.26%).The Mutual Fund holding in Senores Pharmaceuticals was at 5.07% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Senores Pharmaceuticals was at 3.64% in 31 Mar 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 15, 2026, 10:07 AM UTC
- Debt To EquityHigher than industry0.37The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.46The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Senores Pharmaceuticals News
Senores Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Divi's Laboratories | 7,305.00 | 1.67 | 1,93,924.79 | 78.61 | 11.52 | 0.46 | 0.01 |
| Cipla | 1,436.00 | -0.18 | 1,16,006.59 | 22.95 | 3.87 | 0.87 | 0.81 |
| Dr Reddy's Laboratories | 1,230.00 | -1.26 | 1,02,660.32 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | 1,954.15 | 0.72 | 4,68,855.00 | 36.24 | 5.77 | 0.92 | 0.50 |
| Torrent Pharmaceuticals | 4,980.00 | 0.18 | 1,68,598.41 | 67.32 | 17.1 | 0.83 | 17.62 |
Mutual Fund Ownership
View allSenores Pharmaceuticals Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-14 | Audited Results |
| 2026-01-20 | Quarterly Results & Others |
| 2026-01-07 | Others |
| 2025-11-06 | Quarterly Results |
| 2025-07-23 | Quarterly Results & Others |
About the company Senores Pharmaceuticals
- IndustryBiotechnology & Drugs
- ISININE0RB801010
- BSE Code544319
- NSE CodeSENORES
Senores Pharmaceuticals Limited is an India-based pharmaceutical company. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Amphetamine Sulfate Tablets USP, 5 mg and 10 mg; Hydroxychloroquine Sulfate Tablets USP, 200 mg; Ketoconazole Tablets USP, 200 mg; Chlorzoxazone Tablets USP, 250 mg; 5Chlorzoxazone Tablets USP, 500 mg; Ketorolac Tromethamine Tablets USP, 10 mg; Diclofenac Potassium Tablets USP, 25 mg; Diclofenac Potassium Tablets USP, 50 mg, and others. It supplies affordable APIs to generic formulations manufacturers. Its product API include Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Azithromycin for Injection; Meropenem Injection; Ferric Carboxymaltose Injection; Meropenem and Sulbactam for Injection, and others.
Senores Pharmaceuticals Share Price FAQs
Senores Pharmaceuticals is trading at 1480.95 as on Wed Jul 15 2026 09:50:43. This is 2.11% upper as compared to its previous closing price of 1450.40.
The market capitalization of Senores Pharmaceuticals is 6820.30 Cr as on Wed Jul 15 2026 09:50:43.
The average broker rating on Senores Pharmaceuticals is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Senores Pharmaceuticals is 1486.70 whereas the 52 wk low is 601.30
Senores Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 28.78
- Sector P/E: 25.20
- Dividend Yield: 0.00%
- D/E ratio: -
Senores Pharmaceuticals reported a net profit of 115.37 Cr in 2026.
The Mutual Fund Shareholding was 5.07% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Senores Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.